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Background: Patients who have asthma-related emergency department (ED) visits or hospital-
izations are at risk for recurrent exacerbation events. Our objectives were to assess whether
receiving a controller medication at discharge affects risk of recurrence and whether delaying
controller initiation alters this risk.
Methods: Asthma patients with an ED visit or inpatient (IP) stay who received a controller
dispensing within 6 months were identified from healthcare claims. Cox proportional hazards
of the time to first recurrence of an asthma-related ED or IP visit in the 6-month period
following the initial event were constructed, with time following discharge without controller
medication as the primary predictor.
Results: A total of 6139 patients met inclusion criteria, 78% with an ED visit and 22% with an IP
visit; 15% had a recurrence within 6 months. The adjusted hazard ratio (HR) associated with
not having controller medication at discharge was 1.79 (95% confidence interval [CI], 1.42
e2.25). The controller-by-time interaction was significant (P< 0.001), with hazard rising as
time-to-controller initiation increased. Delaying initiation by 1 day approximately tripled
the risk (HR 2.95; 95%CI 1.48e5.88). Sensitivity analyses, including accounting for controller
fills prior to the index event, did not substantially alter these results.
Conclusions: This observational study shows that the risk of a recurrent asthma-related ED visit
or IP stay increased as the time to initiate a controller increased. Our findings support the; COPD, Chronic obstructive pulmonary disease; ED, Emergency department; HR, Hazard ratio; ICD-9-
eases, Ninth Revision, Clinical Modification; ICS, Inhaled corticosteroid; IP, Inpatient; LABA, Long-
steroid; SABA, Short-acting beta-agonist; SD, Standard deviation.
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Asthma exacerbations are acute episodes of symptom
worsening. Mild exacerbations are typically managed with
quick-relief medications at home,1 but more severe exac-
erbations may necessitate a physician office visit, emer-
gency department (ED) visit, or hospitalization.1,2 United
States national survey data indicate that patients had
approximately 1.75 million asthma-related ED visits and
456,000 hospitalizations in 2007.3
Asthma patients who have ED visits or hospitalizations
due to exacerbations are at risk for recurrent events.4e6
Therefore, practice guidelines recommend that physicians
provide a discharge plan including measures to prevent
future exacerbations as well as to address the current
exacerbation.1,2 ED and hospital physicians should consider
prescribing a long-term controller medication at discharge,
such as an inhaled corticosteroid (ICS), for patients who do
not currently use a controller, in addition to continued
short-term treatment with a short-acting beta-agonist
(SABA) and systemic corticosteroids.1,2,7
Controller use after an acute event has been shown to
help prevent repeat asthma-related ED visits and hospital-
izations.8e12 Sin et al.10 showed that patients who used an
ICS after discharge from asthma-related ED visits had 45%
fewer subsequent ED visits over follow-up of at least 2
years. Rowe et al.12 reported that the proportion of
patients that had healthcare visits in the 3 weeks following
ED treatment for an acute asthma event was lower for
those who were randomly assigned to receive budesonide
versus placebo upon discharge. In other analyses, children
who used inhaled budesonide within 30 days of discharge9
and patients who used inhaled anti-inflammatory medica-
tion within 100 days of discharge11 had reduced risk of
recurrent ED visits or hospitalizations over the following
year. These previous controlled trials and observational
studies examined the effect of starting controller medica-
tion at discharge or within a specific timeframe, but did not
assess the effect of delay.
To further investigate the impact of initiating
a controller after an acute asthma event, we assessed the
association between receiving controller medication at
discharge and risk of recurrent events; and the change in
risk if controller initiation is delayed.
Methods
Data sources and patient sample
Two healthcare claims databases with de-identified
medical and pharmacy data were used in this retrospec-
tive analysis: the Life Sciences Research Database and the
IMPACT databases affiliated with OptumInsight; onlyOptumInsight data were used for patients appearing in both
data sources. Administrative claims data in the Life
Sciences Research Database includes medical claims,
pharmacy claims, and eligibility information from a large
national US health plan. The individuals covered by this
health plan are geographically diverse across the US, with
greatest representation in the South and Midwest US census
regions. The plan provides fully insured coverage for
professional (e.g., physician), facility (e.g., hospital), and
outpatient prescription medication services. The IMPACT
database contains similar data elements and geographic
coverage, but includes data from over 46 health plans.
In order to focus on patients with persistent asthma
(i.e., patients who would be candidates for a controller at
ED/hospital discharge), commercial and Medicaid health
plan members with evidence of an asthma-related ED visit
or hospitalization followed by a controller fill were iden-
tified (Fig. 1). Specifically, patients with ED or inpatient
claims with asthma diagnosis (International Classification
of Diseases, Ninth Revision, Clinical Modification [ICD-9-
CM] 493.xx) in a primary diagnosis field or asthma diag-
nosis in a secondary field and respiratory diagnosis
(466.xx, 48x.xx, or 49x.xx [except asthma]) in a primary
field during the identification period 01 Jan 2004e31 Oct
2008 (Life Sciences), or 01 Jan 2005e31 Oct 2008 (IMPACT)
were identified. The discharge date of the earliest
occurring ED visit or hospitalization was defined as the
index date.
A controller fill in the 6 months following the index
date was required. Analysis was focused on patients
whose first controller was an ICS, leukotriene modifier, or
ICS/long-acting beta-agonist (LABA) combination13
because only approximately 2% of patients with a quali-
fying index event filled a different type of controller first
in the follow-up period. “On discharge” fills occurred
0 days post-index (discharge date) or they could be 1 day
prior to discharge for patients with hospitalization index
events.
In addition to the index event and follow-up controller
requirements, patients were required to be at least 4 years
of age and to be continuously enrolled in the health plan for
the 12 months prior to the index date (baseline period) and
6 months following the index date. They were also required
to have an asthma diagnosis in a primary or secondary
diagnosis field and evidence of asthma treatment in the
baseline period. Asthma treatment could have been quick-
relief (SABAs, oral corticosteroids [OCS]) or controller
medications (ICS, LABA, ICS/LABA combination, mast cell
stabilizers, leukotriene modifiers, methylxanthines, immu-
nomodulator). However, patients with claims history indi-
cating controller pharmacy dispensing or administration
within 6 months prior to the index event were excluded.
This criterion was intended to reduce the possible influence
of patients who might have been able to use controller
Figure 1 Sequential sample selection process. Abbreviations: COPD, chronic obstructive pulmonary disease; ICS, inhaled
corticosteroid; LABA, long-acting beta-agonist. *Asthma-related visits required asthma diagnosis (ICD-9-CM 493.xx) in a primary
diagnosis field or asthma diagnosis in a secondary field and respiratory diagnosis (466.xx, 48x.xx, or 49x.xx [except asthma]) in
a primary diagnosis field. y01 January 2004 (OptumInsight database) and 01 January 2005 (IMPACT database) through 31 October
2008. zIndex date defined as the discharge date of the first asthma-related inpatient or emergency department visit during the
identification period.
Controller medication delay and recurrence risk 1633medication from an earlier fill, but who did not have
a controller dispensed immediately at discharge.
Patients who had an inpatient index event of more than
14 days duration or who had a diagnosis of cystic fibrosis
(277.0x) or chronic obstructive pulmonary disease (491.0x,
491.1x , 491.2x , 491.8x, 491.9x, 492.xx, 494.xx, 496.xx, or
filled prescription for anticholinergics) on a claim during
the study period were excluded.
No identifiable protected health information was
extracted or accessed during the course of the study. Pur-
suant to the Health Insurance Portability and Accountability
Act,14 the use of de-identified data does not require insti-
tutional review board approval or waiver of authorization.Outcome measure
Asthma-related ED visits and hospitalizations during the 6-
month post-index period (ie, recurrences) were identified
using the same criteria as for the index event. Patients
were observed until the first post-index recurrence or the
end of the 6-month follow-up period.Time-to-event analysis
Cox proportional hazards models of the time to first
asthma-related ED visit or hospitalization were con-
structed. The primary predictor of interest was time
without controller medication following discharge. Time-
to-controller use was included as a time-varying covariate
(ie, time-to-controller use interacted with elapsed time).
The full primary model adjusted for data source, insurance
type, age, sex, geographic region, index month/year, index
season, index event, asthma as primary diagnosis for index
event (yes/no), Charlson comorbidity index15 (calculated
based on baseline period claims), number of pre-index
controller and rescue medication fills, and number of pre-
index all-cause and asthma-related ambulatory visits, ED
visits, and hospitalizations (by definition, ED visits and
hospitalizations must have been prior to the identification
period).
Four sensitivity analyses were carried out. In the first,
patients with events in the 2 weeks following the index
event were excluded from the primary model in order to
address concerns that these secondary events were related
1634 R.H. Stanford et al.to the index event rather than a recurrence. In the second,
patients with evidence of controller use in the year prior to
the index date were excluded to address the possibility that
patients might have had medication available from an
earlier fill. The third sensitivity analysis stratified patients
according to the index event (ED visit or hospitalization). In
the fourth analysis, acute asthma-related office visits
(defined as a physician or urgent care visit with asthma
diagnosis followed by an OCS prescription fill or an asthma-
related office administration of systemic corticosteroid or
SABA within 7 days following the visit) were added to the
definition of “recurrence.”
Two additional models were developed to characterize
the pattern of change in risk with increasing delays.
Controller initiation during 45-day increments following
discharge was investigated in the first model. The 45-day
increment was chosen empirically to ensure that the
number of patients contributing data to each increment
across the follow-up period was sufficient for meaningful
analysis. In the second the hazard associated with a single
day delay was determined. All models were adjusted for
the same covariates.
Statistical analyses
Patient characteristics are presented descriptively. Means
and standard deviations (SD) are provided for continuous
variables. Wald confidence limits were estimated for the
percentage of patients with a repeat asthma-related ED
visit or hospitalization based on the normal approximation
to the binomial distribution. Statistical significance in the
Cox proportional hazards models was defined using
a threshold of two-sided P< 0.05. All analyses were con-
ducted using SAS 9.1 (SAS Institute, Cary, NC).
Results
Baseline and index event characteristics
A total of 6139 patients met all inclusion and exclusion
criteria (Fig. 1); 55% were from the Life Sciences database
and 45% from IMPACT. Patient sample baseline character-
istics are shown in Table 1. The mean (SD) age was
22.4 17.3 years and 55% were aged less than 18 years. For
the overall sample, the mean Charlson comorbidity score
was 1.14 0.57 indicating relatively low comorbidity
burden. In the pre-index period, 88% of patients filled
a SABA, 51% filled an OCS, and 37% filled a controller (for
controllers, fills occurred from 6 to 12 months pre-index).
Most index events were ED visits (78%) and fewer were
hospitalizations (22%). For 90% of index events, asthma
diagnosis was in the primary position on at least 1 claim.
The duration of index hospitalizations ranged from 2
through 13 days (intraquartile range 3e4 days).
The controller and quick-relief medications patients
received during follow-up are shown in Table 2. Most
patients (80%) filled an ICS as the first controller and 29%
had a leukotriene modifier as their index controller (Table
2). One-quarter (25%) of patients had evidence of
controller initiation at discharge and 43% filled their first
controller from 1 through 30 days post-discharge.Recurrent events
Approximately 15% of patients (95%CI 14e16%) in the
analysis had a repeat asthma-related ED visit or hospitali-
zation within 6 months of the initial event. The fully
adjusted Cox proportional hazards model for having
a recurrent event, presented in Table 3, shows that the risk
increased as the time to initiate a controller increased.
After adjustment, the estimated hazard ratio (HR) associ-
ated with not filling a controller at discharge was 1.79 (95%
CI 1.42e2.25). The significant controller-by-time interac-
tion (P< 0.001) indicates that the hazard increased with
controller initiation delay. The change in the HR with
increasing time-to-controller initiation is illustrated in
Fig. 2.
The sensitivity analyses did not substantially alter the
interpretation of the results. Fully adjusted models
excluding patients with events in the first 2 weeks following
the index event (initial HR 1.33; 95%CI 0.97e1.83; with
significant increase over time; P< 0.001) or excluding
patients with claims for controllers in the year prior to the
index date (initial HR 1.91; 95%CI 1.45e2.53; with signifi-
cant increase over time; P< 0.001) yielded results similar
to the primary model (Fig. 2). Patients with an index ED
event (initial HR 1.63; 95%CI 1.28e2.08; with significant
increase over time; P< 0.001) or an index hospitalization
(initial HR 1.67; 95%CI 0.77e3.60; with nonsignificant
increase over time; PZ 0.10) also had HRs similar to the
primary model (Fig. 2). The reduced significance for the
index hospitalization interaction term is likely due to the
rarity of events, smaller sample size (nZ 1331), and
reduced power to detect interaction effects. Allowing the
subsequent event to be an ED visit, hospitalization, or
acute asthma-related physician office visit also showed that
recurrence risk increased if the controller was not initiated
at discharge (initial HR 2.06; 95%CI 1.79e2.38) and that
hazard increased with greater delay (P< 0.001).
The models of incremental delay showed that the risk of
recurrent events remained relatively flat for controller
initiation within the first 90 days and then increased
thereafter. Specifically, the HRs for a recurrent ED visit or
hospitalization for patients who initiated a controller
within the first 45 days or from 46 through 90 days following
discharge relative to those who received a controller at
discharge were 2.30 (95%CI 1.86e2.85) and 2.51 (95%CI
1.88e3.35), respectively. The HR increased for patients
starting a controller from 91 through 135 days following
discharge (HR 5.46; 95%CI 3.97e7.52) and from 136 through
180 days following discharge (HR 8.13; 95%CI 5.16e12.79).
The hazard for recurrent events for patients who received
a controller the day after discharge was approximately
triple that of patients who received a controller upon
discharge (HR 2.95; 95%CI 1.48e5.88).Discussion
This analysis of patients with persistent asthma who initi-
ated a controller within 6 months following an asthma-
related ED visit or hospitalization suggests that recurrent
events can be prevented by starting the controller imme-
diately at discharge. Our findings are consistent with
Table 1 Patient characteristics by time-to-controller medication fill.
Total
(NZ 6139)
Number of days to controller initiation following index event discharge
0 Days
(nZ 1538)
1e30 Days
(nZ 2645)
31e60 Days
(nZ 673)
61e90 Days
(nZ 415)
91e120 Days
(nZ 344)
121e150 Days
(nZ 285)
151e180 Days
(nZ 239)
Age; n (%)
4e17 3348 (55) 867 (56) 1452 (55) 345 (51) 237 (57) 177 (51) 146 (51) 124 (52)
18e55 2484 (40) 603 (39) 1063 (40) 292 (43) 157 (38) 145 (42) 123 (43) 101 (42)
56 307 (5) 68 (4) 130 (5) 36 (5) 21 (5) 22 (6) 16 (6) 14 (6)
Sex; n (%)
Male 2747 (45) 716 (47) 1184 (45) 303 (45) 190 (46) 148 (43) 111 (39) 95 (40)
Female 3392 (55) 822 (53) 1461 (55) 370 (55) 225 (54) 196 (57) 174 (61) 144 (60)
Racea; n (%)
White 1722 (51) 464 (49) 704 (52) 211 (56) 101 (44) 96 (49) 87 (55) 59 (46)
African-American/Black 352 (10) 88 (9) 132 (10) 39 (10) 33 (14) 29 (15) 14 (9) 17 (13)
Native
Hawaiian/other
Pacific Islander
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
American
Indian/Alaska
Native
7 (0) 2 (0) 2 (0) 0 (0) 0 (0) 0 (0) 2 (1) 1 (1)
Asian 50 (1) 15 (2) 26 (2) 1 (0) 4 (2) 1 (1) 2 (1) 1 (1)
Hispanic 290 (9) 100 (11) 101 (7) 29 (8) 21 (9) 18 (9) 12 (8) 9 (7)
Other 31 (1) 11 (1) 14 (1) 1 (0) 1 (0) 2 (1) 0 (0) 2 (2)
Unknown 951 (28) 266 (28) 387 (28) 99 (26) 69 (30) 50 (26) 40 (25) 40 (31)
Region; n (%)
Northeast 2578 (42) 527 (34) 1239 (47) 295 (44) 167 (40) 140 (41) 117 (41) 93 (39)
Midwest 1424 (23) 361 (23) 570 (22) 165 (25) 103 (25) 97 (28) 73 (26) 55 (23)
South 1473 (24) 454 (30) 574 (22) 144 (21) 101 (24) 73 (21) 61 (21) 66 (28)
West 664 (11) 196 (13) 262 (10) 69 (10) 44 (11) 34 (10) 34 (12) 25 (10)
Insurance type; n (%)
Commercial 5332 (87) 1327 (86) 2303 (87) 583 (87) 358 (86) 297 (86) 248 (87) 216 (90)
Medicaid 807 (13) 211 (14) 342 (13) 90 (13) 57 (14) 47 (14) 37 (13) 23 (10)
Season of index date; n (%)
Winter 1795 (29) 453 (29) 754 (29) 211 (31) 127 (31) 117 (34) 84 (29) 49 (21)
Spring 1765 (29) 467 (30) 784 (30) 174 (26) 87 (21) 80 (23) 93 (33) 80 (33)
Summer 926 (15) 221 (14) 388 (15) 97 (14) 70 (17) 68 (20) 35 (12) 47 (20)
Fall 1653 (27) 397 (26) 719 (27) 191 (28) 131 (32) 79 (23) 73 (26) 63 (26)
Index year; n (%)
2004 1046 (17) 306 (20) 380 (14) 132 (20) 70 (17) 60 (17) 59 (21) 39 (16)
2005 1830 (30) 463 (30) 778 (29) 219 (33) 127 (31) 96 (28) 79 (28) 68 (28)
2006 1423 (23) 302 (20) 667 (25) 137 (20) 98 (24) 91 (26) 65 (23) 63 (26)
2007 1286 (21) 316 (21) 577 (22) 125 (19) 89 (21) 75 (22) 54 (19) 50 (21)
2008 554 (9) 151 (10) 243 (9) 60 (9) 31 (7) 22 (6) 28 (10) 19 (8)
Pre-index medications; n (%)
Controller medicationb 2250 (37) 503 (33) 929 (35) 279 (41) 181 (44) 148 (43) 117 (41) 93 (39)
SABA 5382 (88) 1336 (87) 2318 (88) 606 (90) 363 (87) 300 (87) 250 (88) 209 (87)
OCS 3114 (51) 809 (53) 1313 (50) 345 (51) 212 (51) 171 (50) 143 (50) 121 (51)
SABA, short-acting beta-agonist; OCS, oral corticosteroid.
a Race information was available for patients in the OptumInsight database only; percentages are reported for OptumInsight database
patients only (nZ 3403).
b Controller medication claims could only have been dated during pre-index months 6e12; controllers include: inhaled corticosteroids
(ICS), long-acting beta-agonist (LABA), ICS/LABA combination, mast cell stabilizers, leukotriene modifiers, methylxanthines,
immunomodulator.
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Table 2 Medications during follow-up.
Total
(NZ 6139)
Number of days to controller initiation following index event discharge
0 Days
(nZ 1538)
1e30 Days
(nZ 2645)
31e60 Days
(nZ 673)
61e90 Days
(nZ 415)
91e120 Days
(nZ 344)
121e150 Days
(nZ 285)
151e180
Days (nZ 239)
Index (first) controller medicationa
ICSb 4916 (80) 1322 (86) 2093 (79) 512 (76) 322 (78) 255 (74) 216 (76) 196 (82)
Leukotriene modifier 1801 (29) 413 (27) 778 (29) 212 (32) 132 (32) 110 (32) 90 (32) 66 (28)
Any follow-up controller medicationc
ICSb 5271 (86) 1408 (92) 2273 (86) 553 (82) 346 (83) 269 (78) 222 (78) 200 (84)
ICS monotherapy 3025 (49) 862 (56) 1337 (51) 282 (42) 186 (45) 140 (41) 114 (40) 104 (44)
Fluticasone/salmeterol 2550 (42) 655 (43) 1088 (41) 295 (44) 168 (40) 136 (40) 111 (39) 97 (41)
Budesonide/formoterol 11 (0.2) 2 (0.1) 8 (0.3) 1 (0.2) 0 (0) 0 (0) 0 (0) 0 (0)
Leukotriene modifiers 2338 (38) 588 (38) 1030 (39) 266 (40) 153 (37) 130 (38) 103 (36) 68 (28)
LABA monotherapy 26 (0.4) 8 (0.5) 12 (0.5) 3 (0.5) 3 (0.7) 0 (0) 0 (0) 0 (0)
Mast cell stabilizers 16 (0.3) 3 (0.2) 11 (0.4) 1 (0.2) 0 (0) 0 (0) 1 (0.4) 0 (0)
Methylxanthines 11 (0.2) 3 (0.2) 2 (0.1) 3 (0.5) 1 (0.2) 2 (0.6) 0 (0) 0 (0)
Omalizumab 6 (0.1) 1 (0.1) 3 (0.1) 2 (0.3) 0 (0) 0 (0) 0 (0) 0 (0)
Quick-relief medication
SABA 5037 (82) 1270 (83) 2133 (81) 561 (83) 351 (85) 283 (82) 245 (86) 194 (81)
OCS 3641 (59) 685 (45) 1719 (65) 428 (64) 275 (66) 221 (64) 179 (63) 134 (56)
ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; OCS, oral corticosteroid; SABA, short-acting beta-agonist.
a By definition, the first controller medication could be an inhaled corticosteroid or leukotriene modifier. Patients could have claims
for both types of medication on the same date.
b Includes monotherapy and LABA combinations.
c Includes the first controller and any subsequent controller medications.
1636 R.H. Stanford et al.previous studies reporting that initiating a controller
following a hospital event was associated with reduced
recurrence risk.8e12 Our analyses add to previous research
by showing that even short delays were associated with
increased risk of recurrent events, and risk accumulated as
time elapsed.
A cause and effect relationship between delayed
controller use and ED event/hospitalization recurrence is
plausible, but we cannot exclude an alternative explana-
tion: late filling of a controller prescription might also be
a marker of impending exacerbation. That is, patients
might respond to increasing symptoms by seeking additional
asthma therapy. Although late controller prescription
dispensing could be both a marker of exacerbation and
a measure of lost therapeutic opportunity, we doubt that
the former was a major factor in our findings. Recurrence
risk is highest in the first few weeks following the index
event and prescription filling behavior as a marker of
recurrence would have obscured the time delay relation-
ship we observed.
Although practice guidelines recommend that physicians
consider initiating or continuing controller medication upon
discharge for exacerbation events,1,2 studies have shown
that ED physicians infrequently prescribe controllers.16,17 A
survey of pediatric emergency medicine physicians found
that almost all thought that children with persistent asthma
should be treated with long-term controllers, but less than
20% prescribed a controller at ED discharge.16 The main
reason for not prescribing was the belief that it was the
responsibility of the primary care physician or asthma
specialist.16 Based on retrospective review of electronicmedical records, Cydulka et al.17 reported that 24% of
patients who received ED treatment for an acute asthma
exacerbation received an ICS upon discharge, but another
8% had a controller added in primary care within 6 months.
Our study supports efforts to bridge the gap between acute
and primary asthma care with ED or hospital-initiated
prescribing of a controller prescription and patient educa-
tion to reinforce the importance of filling and using
controller medication upon discharge.1,2
Claims data provide information regarding real-world
healthcare resource use, but analyses of these data are
subject to certain limitations. Patients in the study were all
managed care enrollees, and the findings might not
generalize to uninsured populations. Claims provide
evidence that prescriptions were filled, but whether
patients used their medication as prescribed is not known.
Thus, it is possible that some patients who filled controllers
after their initial event were in fact untreated. Conversely,
some patients we considered untreated might have had
medication on hand from earlier fills. We mitigated the
possible influence of such patients with eligibility rules
excluding patients with recent controller fills and with
sensitivity analysis. Our analyses did not include patients
using controller therapy in the six months prior to the index
event and we cannot be certain that the same recurrence
phenomena would be seen in those continuously adherent
to controller therapy.
Factors other than use of controller medications, such as
the presence of exacerbation triggers including allergens,
infections, or pollution, could influence the occurrence of
asthma-related ED visits and hospitalizations. Although
Table 3 Cox proportional hazards model of subsequent asthma-related ED visits/hospitalizations.
Parameter Parameter estimate Hazard ratio 95% Confidence
interval
P value
No controller medication 0.583 1.79 1.42 2.25 <0.001
No controller medication time 0.008 1.01 1.01 1.01 <0.001
OptumInsight data source (ref: IMPACT) 0.071 0.93 0.78 1.11 0.43
Age 0.005 1.00 0.99 1.00 0.04
Male 0.040 0.96 0.84 1.11 0.58
Geographic region (ref: West)
Northeast 0.025 0.98 0.78 1.23 0.83
Midwest 0.130 0.88 0.69 1.12 0.29
South 0.053 0.95 0.74 1.21 0.67
Medicaid insured (ref: Commercial) 0.363 1.44 1.20 1.72 <0.001
Index month/year 0.013 0.99 0.98 0.99 <0.001
Index season (ref: Fall)
Winter 0.033 0.97 0.81 1.15 0.71
Spring 0.199 0.82 0.69 0.98 0.03
Summer 0.132 0.88 0.71 1.08 0.22
Index hospitalization (ref: ED) 0.343 0.71 0.59 0.86 <0.001
Primary asthma diagnosis for index event 0.361 1.43 1.11 1.85 0.01
Baseline Charlson score 0.100 0.90 0.78 1.05 0.17
Pre-index controller medication fills 0.015 0.99 0.93 1.05 0.63
Pre-index SABA fills 0.033 1.03 1.02 1.05 <0.001
Pre-index OCS fills 0.039 1.04 0.99 1.10 0.15
Pre-index inpatient stays 0.234 1.26 1.08 1.47 0.003
Pre-index ED visits 0.055 1.06 1.03 1.08 <0.001
Pre-index ambulatory visits 0.004 1.00 0.99 1.00 0.24
Pre-index asthma-related inpatient stays 0.095 0.91 0.58 1.41 0.67
Pre-index asthma-related ED visits 0.214 1.24 1.15 1.33 <0.001
Pre-index asthma-related ambulatory visits 0.018 1.02 0.99 1.05 0.21
NZ 6139; number of eventsZ 916.
SABA, short-acting beta-agonist; ED, emergency department; OCS, oral corticosteroid; ref, reference.
Controller medication delay and recurrence risk 1637information on environmental factors was not available for
this analysis, exposure to such triggers could vary by season
or region and all of the proportional hazards models con-
structed for this study adjusted for these factors.Figure 2 Hazard ratios of recurrent events over time: no
controller fill vs. controller fill.The data were limited in their ability to verify whether
prescribing a controller upon discharge was clinically indi-
cated for individual patients. Many different criteria have
been used to define asthma exacerbations for research
purposes, including clinical assessments of lung function,
use of systemic corticosteroids, and the occurrence of
asthma-related ED visits and hospitalizations.18 Although
quantifiable thresholds for lung function are included in
definitions of severe exacerbations,1,2 no measures of
clinical severity (e.g., lung function) were available in this
study and the degree of symptom worsening that brings
a patient to the ED or hospital is subjective. However,
guidelines recommend discharging patients with a daily
controller when there is evidence of persistent asthma.1,19
Almost all asthma patients who have an ED visit or hospi-
talization meet these criteria and are candidates for
a controller prescription upon discharge.19 All patients
included in our study filled a controller prescription within
6 months following an ED visit or hospitalization, which
suggests that they had persistent asthma and were there-
fore candidates to receive a controller immediately.
1638 R.H. Stanford et al.Practice guidelines recommend that patients with
persistent asthma initiate a controller upon discharge from
an acute asthma-related ED visit or hospitalization, and our
findings support the importance of early initiation in
reducing the risk of recurrence. Acute care providers should
provide controller prescriptions to patients with persistent
asthma after exacerbation events, and thereby help to
bridge the gap between acute and primary care.
Conflicts of interest
RHS is employed by GlaxoSmithKline. ARB, AAR, and GGR
are employed by OptumInsight, which was contracted by
GlaxoSmithKline to conduct the study. CAC has served as
a consultant to AstraZeneca, Dey, Genentech, Glax-
oSmithKline, Merck, Novartis, Pfizer, and sanofi-aventis.
KRC holds the GSK-CIHR Research Chair in Respiratory
Healthcare Delivery at the University Health Network, has
served as a consultant to CSL Behring, GlaxoSmithKline,
Novartis, Nycomed (Takeda), and Talecris (Grifols), and has
received payment for lectures or service on speakers
bureaus from Boehringer-Ingelheim, GlaxoSmithKline, Gri-
fols, Nycomed (Takeda), Family Physicians Airways Group of
Canada, Canadian Network for Respiratory Care, and
Talecris.
Acknowledgments
This study was funded by GlaxoSmithKline, Research
Triangle Park, North Carolina. The study sponsor was not
involved in the study design, collection, analysis, or inter-
pretation of data, the writing of the manuscript, or the
decision to submit the manuscript for publication beyond
the role of RHS as a study author.
The authors thank Suzanne Adams and Randy Gerdes for
programming the data set, Lee Brekke, PhD, Brett Pinsky,
MPH, and Ying Fan, MS for assistance with statistical anal-
ysis, and Elizabeth J. Davis, PhD, for medical writing
assistance; all from OptumInsight, Eden Prairie, MN. Fund-
ing for manuscript preparation was provided to OptumIn-
sight by GlaxoSmithKline. Findings from this study were
presented at the 2011 International Conference of the
American Thoracic Society.
References
1. National Asthma Education and Prevention Program. Expert
panel report 3: guidelines for the diagnosis and management
of asthma. National Heart Lung and Blood Institute. Available
from: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.
pdf; 2007.
2. Global Initiative for Asthma (GINA). GINA report, global
strategy for asthma management and prevention. GINA Web-
site. Available from: http://www.ginasthma.org; 2011
[accessed July 26, 2012].
3. Akinbami LJ, Moorman JE, Liu X. Asthma prevalence, health
care use, and mortality: United States, 2005e2009. National
Health Statistics Reports; 2011.4. Adams RJ, Smith BJ, Ruffin RE. Factors associated with hospital
admissions and repeat emergency department visits for adults
with asthma. Thorax 2000;55:566e73.
5. Eisner MD, Katz PP, Yelin EH, Shiboski SC, Blanc PD. Risk factors
for hospitalization among adults with asthma: the influence of
sociodemographic factors and asthma severity. Respir Res
2001;2:53e60.
6. Miller MK, Lee JH, Miller DP, Wenzel SE. Recent asthma exac-
erbations: a key predictor of future exacerbations. Respir Med
2007;101:481e9.
7. Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW.
Corticosteroids for preventing relapse following acute exac-
erbations of asthma. Cochrane Database Syst Rev 2007:
CD000195.
8. Silverman RA, Nowak RM, Korenblat PE, et al. Zafirlukast
treatment for acute asthma: evaluation in a randomized,
double-blind, multicenter trial. Chest 2004;126:1480e9.
9. Camargo Jr CA, Ramachandran S, Ryskina KL, Lewis BE,
Legorreta AP. Association between common asthma therapies
and recurrent asthma exacerbations in children enrolled in
a state Medicaid plan. Am J Health Syst Pharm 2007;64:
1054e61.
10. Sin DD, Man SF. Low-dose inhaled corticosteroid therapy and
risk of emergency department visits for asthma. Arch Intern
Med 2002;162:1591e5.
11. Smith MJ, Rascati KL, McWilliams BC. Inhaled anti-
inflammatory pharmacotherapy and subsequent hospitaliza-
tions and emergency department visits among patients with
asthma in the Texas Medicaid program. Ann Allergy Asthma
Immunol 2004;92:40e6.
12. Rowe BH, Bota GW, Fabris L, Therrien SA, Milner RA, Jacono J.
Inhaled budesonide in addition to oral corticosteroids to
prevent asthma relapse following discharge from the emer-
gency department: a randomized controlled trial. JAMA 1999;
281:2119e26.
13. Use of appropriate medications for people with asthma: Table
ASM-D/Table DASM-D: preferred asthma therapy medications.
National Committee for Quality Assurance (NCQA). HEDIS 2011
Final NDC Lists; Available from: http://www.ncqa.org/tabid/
1274/Default.aspx; 2010 November 15 [accessed October 12,
2011].
14. Health insurance portability and accountability act of 1996.
Public law 104-191, 104th congress. U.S. Department of Health
& Human Services. Available from: http://www.cms.hhs.gov/
HIPAAGenInfo/Downloads/HIPAALaw.pdf; 1996 [accessed
January 12, 2010].
15. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for
defining comorbidities in ICD-9-CM and ICD-10 administrative
data. Med Care 2005;43:1130e9.
16. Scarfone RJ, Zorc JJ, Angsuco CJ. Emergency physicians’
prescribing of asthma controller medications. Pediatrics 2006;
117:821e7.
17. Cydulka RK, Tamayo-Sarver JH, Wolf C, Herrick E, Gress S.
Inadequate follow-up controller medications among patients
with asthma who visit the emergency department. Ann Emerg
Med 2005;46:316e22.
18. Reddel HK, Taylor DR, Bateman ED, et al. An official American
Thoracic Society/European Respiratory Society statement:
asthma control and exacerbations: standardizing endpoints for
clinical asthma trials and clinical practice. Am J Respir Crit
Care Med 2009;180:59e99.
19. Krishnan JA, Nowak R, Davis SQ, Schatz M. Anti-inflammatory
treatment after discharge home from the emergency depart-
ment in adults with acute asthma. J Allergy Clin Immunol
2009;124:S29e34.
